Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer

Background While lymph node metastasis is among the strongest predictors of disease-free and overall survival for patients with breast cancer, the immunological nature of tumor-draining lymph nodes is often ignored, and may provide additional prognostic information on clinical outcome. Methods and Findings We performed immunohistochemical analysis of 47 sentinel and 104 axillary (nonsentinel) nodes from 77 breast cancer patients with 5 y of follow-up to determine if alterations in CD4, CD8, and CD1a cell populations predict nodal metastasis or disease-free survival. Sentinel and axillary node CD4 and CD8 T cells were decreased in breast cancer patients compared to control nodes. CD1a dendritic cells were also diminished in sentinel and tumor-involved axillary nodes, but increased in tumor-free axillary nodes. Axillary node, but not sentinel node, CD4 T cell and dendritic cell populations were highly correlated with disease-free survival, independent of axillary metastasis. Immune profiling of ALN from a test set of 48 patients, applying CD4 T cell and CD1a dendritic cell population thresholds of CD4 ≥ 7.0% and CD1a ≥ 0.6%, determined from analysis of a learning set of 29 patients, provided significant risk stratification into favorable and unfavorable prognostic groups superior to clinicopathologic characteristics including tumor size, extent or size of nodal metastasis (CD4, p < 0.001 and CD1a, p < 0.001). Moreover, axillary node CD4 T cell and CD1a dendritic cell populations allowed more significant stratification of disease-free survival of patients with T1 (primary tumor size 2 cm or less) and T2 (5 cm or larger) tumors than all other patient characteristics. Finally, sentinel node immune profiles correlated primarily with the presence of infiltrating tumor cells, while axillary node immune profiles appeared largely independent of nodal metastases, raising the possibility that, within axillary lymph nodes, immune profile changes and nodal metastases represent independent processes. Conclusion These findings demonstrate that the immune profile of tumor-draining lymph nodes is of novel biologic and clinical importance for patients with early stage breast cancer.

[1]  R. Elashoff,et al.  Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node , 2004, Modern Pathology.

[2]  K. Hunt,et al.  Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer , 2004, Breast Cancer Research.

[3]  R. Carlson,et al.  Cytotoxic T Lymphocyte Count and Survival Time in Women with Metastatic Breast Cancer , 2004, The Breast Journal.

[4]  L. J. Veer,et al.  Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers , 2004, British Journal of Cancer.

[5]  H. Thaler,et al.  Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma , 2004, Cancer.

[6]  L. J. Veer,et al.  Discovery of previously undetected micrometastases by mRNA markers in sentinel lymph nodes of breast cancer patients , 2004 .

[7]  L. Sobin,et al.  Classification of isolated tumor cells , 2003, Cancer.

[8]  A. Fattorossi,et al.  Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire , 2003, Immunology.

[9]  M. Sheaff,et al.  The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. , 2003, Surgery.

[10]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[11]  B. Coventry,et al.  CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer , 2003, British Journal of Cancer.

[12]  A. Vincent-Salomon,et al.  Tumor Antigens and Antigen-Presenting Capacity in Breast Cancer , 2003, Pathobiology.

[13]  V. Speights,et al.  Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. , 2003, Archives of pathology & laboratory medicine.

[14]  H. Shinohara,et al.  Prognostic value of tumor‐infiltrating dendritic cells expressing CD83 in human breast carcinomas , 2003, International journal of cancer.

[15]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[16]  E. Portiansky,et al.  Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. , 2002, Immunology letters.

[17]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[18]  L. Tafra.  Sentinel node biopsy for breast cancer. , 2002, Minerva chirurgica.

[19]  A. Cochran,et al.  Sentinel Lymph Nodes Show Profound Downregulation of Antigen-Presenting Cells of the Paracortex: Implications for Tumor Biology and Treatment , 2001, Modern Pathology.

[20]  F. Gambón-Deza,et al.  Changes in human lymphocyte subpopulations in tonsils and regional lymph nodes of human head and neck squamous carcinoma compared to control lymph nodes , 2001, BMC Immunology.

[21]  G. Capitanio,et al.  Sentinel node biopsy in breast cancer. , 2000, Breast.

[22]  D J Spitz,et al.  Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma , 1999, Cancer.

[23]  Coventry Bj.  CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. , 1999 .

[24]  D. Larsimont,et al.  Tumor‐infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome , 1999, International journal of cancer.

[25]  R. Foster,et al.  The sentinel node in breast cancer--a multicenter validation study. , 1998, The New England journal of medicine.

[26]  M. Fan,et al.  Lymph node micrometastases from breast carcinoma , 1997, Cancer.

[27]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[28]  T. Muto,et al.  Functional expression of CD11a on CD8+ cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma , 1996, Cancer.

[29]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[30]  K. Sugimachi,et al.  Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. , 1996, Immunobiology.

[31]  C. Bryan,et al.  Clinical Utility of a Lymph Node Normal Range Obtained by Flow Cytometry , 1993, Annals of the New York Academy of Sciences.

[32]  A. Campbell,et al.  Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. , 1993, Immunology letters.

[33]  E. Korn,et al.  Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. , 1987, Journal of the National Cancer Institute.

[34]  H. Deicher,et al.  Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients , 1979, Cancer.

[35]  O. J. Dunn,et al.  Basic Statistics: a Primer for the Biomedical Sciences , 1962 .

[36]  D. Page,et al.  Routinely available indicators of prognosis in breast cancer , 2004, Breast Cancer Research and Treatment.

[37]  R. Essner,et al.  Dendritic cell function in sentinel nodes. , 2002, Oncology.

[38]  B. Coventry.  CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. , 1999, Anticancer Research.

[39]  B. Coventry,et al.  Identification and isolation of CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. , 1997, Advances in experimental medicine and biology.

[40]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.